Clinical Trials
20 trialsNCT03093116 2026-05-27
TRIDENT-1
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06406465 2026-05-27
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05773274 2026-05-26
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT03412877 2026-05-22
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT04086485 2026-05-22
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT05263050 2026-05-22
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Fox Chase Cancer Center
Phase 2 Recruiting
NCT06263088 2026-05-22
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
Case Comprehensive Cancer Center
Phase NA Recruiting
NCT06430021 2026-05-22
PRO-NEM1
Centre Hospitalier Universitaire Dijon
Recruiting
NCT07377487 2026-05-22
INDIGO
Boston Scientific Corporation
Phase NA Recruiting
NCT05884255 2026-05-19
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT06881992 2026-05-18
Tumor HI
Rezolute
Phase 3 Recruiting
NCT06122610 2026-05-15
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
University of Wisconsin, Madison
Phase 1 Recruiting
NCT05636618 2026-05-14
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Perspective Therapeutics
Phase 1/2 Recruiting
NCT04665739 2026-05-13
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06735560 2026-05-13
ELEGANCE
Nantes University Hospital
Phase NA Recruiting
NCT05918302 2026-05-12
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Recruiting
NCT04888481 2026-05-11
68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
University of Alberta
Phase 2 Recruiting
NCT07129252 2026-05-11
BRAVESST2
Crinetics Pharmaceuticals Inc.
Phase 1/2 Recruiting
NCT02012699 2026-05-05
iCaRe2
University of Nebraska
Recruiting
NCT02402244 2026-05-05
Project: Every Child for Younger Patients With Cancer
Children's Oncology Group
Recruiting